CAR-T-cell-based immunotherapies in hemato-oncology: Focus on use in clinical routine CAR-T-Zell-basierte Immuntherapien in der Hämatoonkologie: Fokus auf den Einsatz in der klinischen Routine
Steinhardt MJ, Reinhardt L, Luu M, Danhof S, Hudecek M (2023)
Publication Type: Journal article
Publication year: 2023
Journal
Book Volume: 29
Pages Range: 160-172
Journal Issue: 2
DOI: 10.1007/s00761-022-01299-1
Abstract
Chimeric antigen receptor (CAR)-T-cell-based therapies are a modern pillar in immunotherapy. They show promising response rates in relapsed/refractory B and plasma cell malignancies. Cancer recurrence after initial response and lack of efficacy against solid tumors are key challenges for health care providers, patients, and researchers in the CAR-T cell therapy. Another problem is the currently limited production capacity. Here, we discuss the challenges for this promising therapy as well as possible solutions and recent innovations. With increased use of CAR-T cell therapy, there is growing experience in recognizing and treating acute and chronic side effects. We provide an update on clinical routine and patient management before, during, and after CAR‑T cell therapy.
Involved external institutions
Germany (DE)How to cite
APA:
Steinhardt, M.J., Reinhardt, L., Luu, M., Danhof, S., & Hudecek, M. (2023). CAR-T-cell-based immunotherapies in hemato-oncology: Focus on use in clinical routine CAR-T-Zell-basierte Immuntherapien in der Hämatoonkologie: Fokus auf den Einsatz in der klinischen Routine. Die Onkologie, 29(2), 160-172. https://doi.org/10.1007/s00761-022-01299-1
MLA:
Steinhardt, M. J., et al. "CAR-T-cell-based immunotherapies in hemato-oncology: Focus on use in clinical routine CAR-T-Zell-basierte Immuntherapien in der Hämatoonkologie: Fokus auf den Einsatz in der klinischen Routine." Die Onkologie 29.2 (2023): 160-172.
BibTeX: Download